Syros (SYRS) in Focus: Stock Moves 7.9% Higher
Syros Pharmaceuticals, Inc. SYRS was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $9.49 to $12.78 in the past one-month time frame.
The company has seen five positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Syros. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Syros has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Syros Pharmaceuticals, Inc. Price
Syros Pharmaceuticals, Inc. price | Syros Pharmaceuticals, Inc. Quote
Investors interested in the Medical – Biomedical and Genetics industry may consider BioTechne Corp TECH which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioTechne Corp (TECH) : Free Stock Analysis Report
Syros Pharmaceuticals, Inc. (SYRS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
